Background: Treatment of chronic ulcers involves addressing
the underlying cause and interventions to improve
the process of healing such as autologous platelet-rich plasma.
Platelet-rich plasma has been extensively studied for its potential
in promoting healing of chronic ulcers as it contains a
high concentration of growth factors such as platelet derived
growth factor, epithelial growth factor and fibroblast growth
factor. Advanced growth factor delivery systems have been developed
to prolong the bio-activity of growth factors.
LGF have been developed by a patented method to overcome
the discrepancies of conventional platelet rich plasma.
Objective: In this study, we present LGFoam as a topical
agent containing Lyophilized growth factors, for use in chronic
lower limb ulcers for the purpose of improving healing.
Methodology: Comparison of ulcer size between LGFoam
topically applied to non-healing lower limb ulcers of various
etiologies, as opposed to conventional dressing with a 30-day
follow-up period.
Conclusion: Several advanced growth factors delivery
systems have been developed for topical use. However, conflicting
evidence exists for their efficacy, warranting further
research.
In our study, there was a statistically significant decrease
in ulcer size for the LGFoam group, encouraging future studies
into its use in promoting wound healing in general, especially
chronic non-healing ulcers as a problematic entity.